Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6930928 | 0.82 | SLC9A1 (0.35) | MAP2K1MAP2K2RIPK1TNIK | |
| SCHEMBL8104506 | 0.78 | IDO1 (0.36) | IDO1SLC6A4SLC6A2 | |
| SCHEMBL15545696 | 0.78 | KDM4E (0.47) | RIPK1SLC6A4SLC6A2 | |
| SCHEMBL10487847 | 0.77 | LOXL2 (0.42) | AKR1B1MAP2K1MAP2K2IDO1SLC6A4 | |
| SCHEMBL30028529 | 0.77 | IDO1 (0.33) | AKR1B1IDO1AGXT | |
| SCHEMBL30028568 | 0.77 | SLC6A4 (0.37) | AKR1B1MAP2K1MAP2K2IDO1SLC6A4 | |
| SCHEMBL1660701 | 0.77 | IDO1 (0.33) | AKR1B1IDO1AGXT | |
| SCHEMBL16589342 | 0.77 | IDO1 (0.33) | AKR1B1MAP2K1MAP2K2IDO1SLC6A4 | |
| SCHEMBL15012263 | 0.77 | SLC6A4 (0.37) | AKR1B1MAP2K1MAP2K2IDO1SLC6A4 | |
| SCHEMBL26586522 | 0.77 | IDO1 (0.33) | AKR1B1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020039092-A2 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2020-02-27 | — | — | WO | disclosed |
| US-9440960-B2 | Substituted oxetanes and their use as inhibitors of cathepsin C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-13 | — | — | US | disclosed |
| EP-2760843-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160031861-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| WO-2012028578-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER CROPSCIENCE AG (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-1780197-B9 | 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-2085391-A2 | Inhibitors of factor XA and other serine proteases involved in the coagulation cascade | Warner-Lambert Company LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2008024724-A1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031861-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | CTSE, CTSC, CTSZ | AKR1B1 870/4885MAP2K1 4608/4885MAP2K2 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.